Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

IL-2 and IL-10 Production by Human CD4+T Cells Is Differentially Regulated by p38: Mode of Stimulation-Dependent Regulation of IL-2

Veiopoulou C.a · Kogopoulou O.a · Tzakos E.a · Mavrothalassitis G.c · Mitsias D.a · Karafoulidou A.b · Paliogianni F.d · Moutsopoulos H.M.a · Thyphronitis G.a

Author affiliations

aDepartment of Pathophysiology, School of Medicine, University of Athens and bBlood Transfusion and Haemophilia Center, Laikon General Hospital, Athens, cSchool of Medicine, University of Crete and IMBB-FORTH, Heraklion, and dDepartment of Microbiology, School of Medicine, University of Patras, Patras, Greece

Related Articles for ""

Neuroimmunomodulation 2004;11:199–208

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: July 09, 2004
Issue release date: July 2004

Number of Print Pages: 10
Number of Figures: 8
Number of Tables: 0

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Abstract

Antigenic stimulation of T cells initiates a complex series of intracellular signaling pathways that target and activate different cytokine genes. The participation of mitogen-activated protein kinases (MAPKs) in these processes has not been studied thoroughly and in some instances conflicting results have been reported. Here we have examined the role of p38 MAPK on IL-2 and IL-10 production following activation of human CD4+ T cells or of the leukemic cell line Hut-78, with either plate-bound anti-CD3 in the presence or absence of soluble anti-CD28 (plCD3, plCD3/sCD28), or with cross-linked anti-CD3 and anti-CD28 (crsCD3+CD28), or with PMA plus ionomycin. Pharmacological inhibition of the p38 pathway with either SB203580, SB202190, or SKF86002 strongly downregulated IL-10 production by T cells stimulated with any of the above treatments. In contrast the effect of p38 inhibition on IL-2 was stimulus dependent. Thus, p38 inhibition strongly upregulated IL-2 production (up to 10-fold) in the plCD3- and plCD3/sCD28-stimulated cultures while it had minimal or no effect in the other two stimulation protocols. Intracellular and mRNA levels of IL-2 and IL-10 were also upregulated and downregulated, respectively, by p38 inhibitors in the plCD3/sCD28-stimulated CD4+ T cells. Also, the induction of IL-2 and the parallel suppression of IL-10 by p38 inhibitors were independent of the balance between these two cytokines, as demonstrated by the addition of exogenous IL-10 or blocking anti-IL-10 antibody in CD4+ and Hut-78 cell cultures. These results show that p38 acts as a molecular switch that changes the balance between IL-2 and IL-10. This is especially important considering the opposing role of these cytokines in peripheral immune tolerance.

© 2004 S. Karger AG, Basel


References

  1. Read S, Powrie F: CD4(+) regulatory T cells. Curr Opin Immunol 2001;13:644–649.
    External Resources
  2. Chai JG, Bartok I, Chandler P, Vendetti S, Antoniou A, Dyson J, Lechler R: Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol 1999;29:686–692.
  3. Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG,Bernstein GM, D’Andrea AD, Ritz J, Nadler LM: Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994;266:1039–1042.
  4. DeSilva DR, Urdahl KB, Jenkins MK: Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991;147:3261–3267.
  5. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10:1969–1980.
  6. de Waal Malefyt R, Yssel H, de Vries JE: Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993;150:4754–4765.
  7. Groux H, Bigler M, de Vries JE, Roncarolo MG: Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184:19–29.
  8. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772–4780.
  9. Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737–742.
  10. Shevach EM: Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423–449.
  11. Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359–368.
    External Resources
  12. Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT: Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 1993;91:1481–1489.
  13. Ramierz F, Fowell DJ, Puklavec M, Simmonds S, Mason D: Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996;156:2406–2412.
  14. van der Poll T, Barber AE, Coyle SM, Lowry SF: Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia – A clinical research center study. J Clin Endocrinol Metab 1996;81:3604–3606.
  15. Dong C, Davis RJ, Flavell RA: MAP kinases in the immune response. Annu Rev Immunol 2002;20:55–72.
  16. Rincon M: MAP-kinase signaling pathways in T cells. Curr Opin Immunol 2001;13:339–345.
  17. Egerton M, Fitzpatrick DR, Kelso A: Activation of the extracellular signal-regulated kinase pathway is differentially required for TCR-stimulated production of six cytokines in primary T lymphocytes. Int Immunol 1998;10:223–229.
  18. Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R: Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol 1998;160:2579–2589.
  19. Koprak S, Staruch MJ, Dumont FJ: A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: Dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol 1999;192:87–95.
  20. Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A: The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 2001;276:13664–13674.
  21. Rayter SI, Woodrow M, Lucas SC, Cantrell DA, Downward J: p21ras mediates control of IL-2 gene promoter function in T cell activation. EMBO J 1992;11:4549–4556.
  22. Izquierdo Pastor M, Reif K, Cantrell D: The regulation and function of p21ras during T-cell activation and growth. Immunol Today 1995;16:159–164.
  23. Baldari CT, Macchia G, Telford JL: Interleukin-2 promoter activation in T-cells expressing activated Ha-ras. J Biol Chem 1992;267:4289–4291.
  24. Genot E, Cleverley S, Henning S, Cantrell D: Multiple p21ras effector pathways regulate nuclear factor of activated T cells. EMBO J 1996;15:3923–3933.
  25. Faris M, Kokot N, Lee L, Nel AE: Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in jurkat T cells. Evidence for the importance of Ras in a pathway that is controlled by dual receptor stimulation. J Biol Chem 1996;271:27366–27373.
  26. Whitehurst CE, Geppert TD: MEK1 and the extracellular signal-regulated kinases are required for the stimulation of IL-2 gene transcription in T cells. J Immunol 1996;156:1020–1029.
  27. Su B, Cheng J, Yang J, Guo Z: MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J Biol Chem 2001;276:14784–14790.
  28. Matsuda S, Moriguchi T, Koyasu S, Nishida E: T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem 1998;273:12378–12382.
  29. Zhang J, Salojin KV, Gao JX, Cameron MJ, Bergerot I, Delovitch TL: p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol 1999;162:3819–3829.
  30. Song GY, Chung CS, Chaudry IH, Ayala A: Immune suppression in polymicrobial sepsis: Differential regulation of Th1 and Th2 responses by p38 MAPK. J Surg Res 2000;91:141–146.
  31. Mori A, Kaminuma O, Miyazawa K, Ogawa K, Okudaira H, Akiyama K: p38 mitogen-activated protein kinase regulates human T cell IL-5 synthesis. J Immunol 1999;163:4763–4771.
  32. Schafer PH, Wadsworth SA, Wang L, Siekierka JJ: p38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J Immunol 1999;162:7110–7119.
  33. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997;272:12116–12121.
  34. Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H, Tocci MJ, O’Keefe SJ, O’Neill EA: The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998;37:13846–13853.
  35. Frasch SC, Nick JA, Fadok VA, Bratton DL, Worthen GS, Henson PM: p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J Biol Chem 1998;273:8389–8397.
  36. Taga K, Tosato G: IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992;148:1143–1148.
  37. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001;166:5530–5539.
  38. Elenkov IJ, Hoffman J, Wilder RL: Does differential neuroendocrine control of cytokine production govern the expression of autoimmune diseases in pregnancy and the postpartum period? Mol Med Today 1997;3:379–383.
  39. Wilder RL: Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 1995;13:307–338.
  40. Kozawa O, Niwa M, Hatakeyama D, Tokuda H, Oiso Y, Matsuno H, Kato K, Uematsu T: Specific induction of heat shock protein 27 by glucocorticoid in osteoblasts. J Cell Biochem 2002;86:357–364.
  41. Lasa M, Abraham SM, Boucheron C, Saklatvala J, Clark AR: Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002;22:7802–7811.
  42. Song GY, Chung CS, Chaudry IH, Ayala A: MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis. Am J Physiol Cell Physiol 2001;281:C662–C669.
  43. Salituro FG, Germann UA, Wilson KP, Bemis GW, Fox T, Su MS: Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases. Curr Med Chem 1999;6:807–823.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: July 09, 2004
Issue release date: July 2004

Number of Print Pages: 10
Number of Figures: 8
Number of Tables: 0

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.